Related Experiment Video
Updated: Aug 30, 2026

Unveiling Histone Proteoforms using 2D-TAU Gel Electrophoresis
Published on: October 18, 2024
Inactivation of a histone methyltransferase by mutations in human cancers
Keun-Cheol Kim1, Liqing Geng, Shi Huang
1Program in Cancer Genetics and Epigenetics, Cancer Research Center, The Burnham Institute, La Jolla, CA 92037, USA.
Abstract:
Histone methyltransferase (HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain, which shares sequence homology with an independently described sequence motif, the PR domain. Intact PR or SET sequence is required for tumor suppression functions, but it remains unclear whether it is histone methyltransferase activity that underlies tumor suppression. We now show that tumor suppressor RIZ1 (PRDM2) methylates histone H3 on lysine 9, and this activity is reduced by mutations in the PR domain found in human cancers. Also, S-adenosylhomocysteine or methyl donor deficiency inhibits RIZ1 and other H3 lysine 9 methylation activities. These results support the hypothesis that H3 lysine 9 methylation activities of a PR/SET domain have tumor suppression functions and may underlie carcinogenesis associated with dietary methyl donor deficiency.
Insights
Histone methyltransferase (HMT) enzymes, including RIZ1, suppress tumors by methylating histone H3. Mutations and methyl donor deficiency impair this crucial HMT activity, potentially leading to cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Histone methyltransferases (HMTs) possess a catalytic SET domain, homologous to the PR domain.
- The PR/SET domain is crucial for tumor suppression, but its specific role remains unclear.
Purpose of the Study:
- To investigate whether histone methyltransferase activity underlies the tumor suppression function of the PR/SET domain.
- To determine the role of RIZ1 (PRDM2) in histone methylation and its connection to cancer.
Main Methods:
- Assessed histone H3 lysine 9 methylation by RIZ1.
- Analyzed the impact of PR domain mutations (found in human cancers) on RIZ1 activity.
- Investigated the effect of S-adenosylhomocysteine and methyl donor deficiency on RIZ1 and H3 lysine 9 methylation.
Main Results:
- RIZ1 (PRDM2) was shown to methylate histone H3 on lysine 9.
- Mutations in the PR domain of RIZ1, prevalent in human cancers, reduced its HMT activity.
- Deficiency in methyl donors or S-adenosylhomocysteine inhibited RIZ1 and other H3 lysine 9 methylation activities.
Conclusions:
- H3 lysine 9 methylation by PR/SET domain-containing proteins, like RIZ1, has tumor suppression functions.
- Impaired HMT activity due to mutations or methyl donor deficiency may contribute to carcinogenesis.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Spreading of Chromatin Modifications
Writers
The writer is an enzyme that can...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Abnormal Proliferation
Histone Variants at the Centromere

